The US Food and Drug Administration’s recent expansion in approval of emtricitabine/tenofovir (Truvada) for preexposure prophylaxis (PrEP) to youth who weigh more than 35 kg was a major gain for efforts to end the HIV epidemic among those aged 13 to 24 years, who accounted for 21% of all new HIV infections nationwide in 2017.1 Nonetheless, PrEP use remains low among individuals in this age group, including those who are sexual and gender minorities (and who are among those at the highest risk of HIV acquisition).2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Saleska JL, Lee S. Normalization of Preexposure Prophylaxis for Adolescents: Empowerment, Not Vulnerability. JAMA Pediatr. 2020;174(12):1133–1134. doi:10.1001/jamapediatrics.2020.2545
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: